Skip to main content

Table 5 Subgroup analysis for progression-free survival, overall survival and objective response rate

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Group PFS OS ORR
No.of studies HR (95% CI) P I2 (%) No.of studies RR (95% CI) P I2 (%) No.of studies RR (95% CI) P I2 (%)
Total 24 1.04 (0.97–1.10) 0.26 38 21 1.04 (0.89–1.21) 0.61 58 13 1.08 (1.00–1.18) 0.06 20
Nation
 Keroa 8 0.89 (0.78–1.02) 0.09 18 8 1.03 (0.85–1.23) 0.79 0 5 1.18 (0.94–1.49) 0.16 0
 China 6 1.05 (0.88–1.25) 0.63 20 5 0.92 (0.62–1.36) 0.67 67 2 0.87 (0.70–1.08) 0.21 0
 Japan 6 1.15 (0.98–1.36) 0.09 20 4 1.04 (0.84–1.27) 0.74 0 3 1.18 (0.98–1.41) 0.08 0
 Taiwan 4 1.09 (0.77–1.54) 0.62 74 4 1.12 (0.75–1.67) 0.59 90 3 1.07 (0.86–1.35) 0.54 71
Tumor stage
 IIIb-IV 22 1.04 (0.98–1.10) 0.23 40 18 1.08 (0.92–1.26) 0.34 53 12 1.09 (1.00–1.18) 0.05 24
 I-IV 2 0.77 (0.39–1.51) 0.45 25 3 0.54 (0.18–1.63) 0.27 80 1 0.46 (0.05–4.01) 0.48 NA
History
 Non-squamous 13 1.04 (0.96–1.14) 0.88 51 11 1.06 (0.86–1.31) 0.58 68 9 1.08 (0.99–1.17) 0.09 42
 Squamous included 10 1.02 (0.94–1.12) 0.6 11 9 0.98(0.86–1.13) 0.81 48 4 1.19 (0.81–1.77) 0.38 0
 Unclear 1 3.05 (0.84–11.09) 0.09 NA 1 1.34 (0.49–3.67) 0.57 NA     
Treatment line
 First line included 14 1.09 (0.98–1.20) 0.11 46 11 0.97 (0.72–1.30) 0.82 77 7 1.06 (0.90–1.25) 0.52 52
 Second line or later 8 1.01 (0.93–1.08) 0.89 22 8 1.02 (0.91–1.14) 0.78 0 6 1.15 (0.98–1.35) 0.08 0
 First line only 3 0.89 (0.32–2.49) 0.82 66 2 0.24 (0.04–1.43) 0.12 75     
 Second line only 3 0.93 (0.76–1.14) 0.5 0 2 1.25 (0.90–1.73) 0.19 0 2 1.18 (0.76–1.82) 0.47 0
 Third line only 1 0.88 (0.43–1.79) 0.72 NA 2 0.96 (0.81–1.14) 0.47 0 1 0.46 (0.05–4.01) 0.48 NA
 Unclear 2 1.48 (0.72–3.08) 0.29 43 2 1.22 (0.62–2.39) 0.56 0     
EGFR mutation
 Partial mutation 11 1.02 (0.91–1.15) 0.68 21 11 1.15 (0.91–1.45) 0.24 68 9 1.10 (1.00–1.21) 0.05 21
 All mutation 9 1.11 (0.90–1.36) 0.33 50 7 0.82 (0.54–1.25) 0.36 59 2 0.88 (0.71–1.09) 0.24 0
 Unclear 4 0.98 (0.76–1.26) 0.88 57 3 0.97 (0.84–1.13) 0.67 0 2 1.22 (0.92–1.62) 0.18 2
Study design
 Retrospective study 21 1.02 (0.95–1.09) 0.37 40 18 1.01 (0.84–1.21) 0.92 63 10 1.10 (1.00–1.22) 0.06 19
 RCT 3 1.11 (0.96–1.27) 0.15 32 3 1.11 (0.93–1.32) 0.25 0 3 1.04 (0.90–1.20) 0.62 36
  1. Abbreviations: PFS progression-free survival, OS overall survival, ORR objective response rate, ORR objective response rate, HR hazard ratio, RR relative risk, RCT randomized controlled trial, NA not available